Skip to content

Pycnogenol

Also called Pine Bark Extract

A standardized pine bark extract with an unusually large trial base for a botanical — largely because it's a single patented extract, so the studies are actually comparable.

  • CategoryCardiovascular
  • FormFrench maritime pine bark extract
  • EvidenceClinical trials on file

Where to get Pycnogenol

iHerb
French maritime pine bark extract

Cam’s partner link opens iHerb on this product. No code needed; the link credits Cam.

Shop on iHerb

The short version

  • What it doesThe extract is a polymer mixture, and the molecule that ends up doing the work is not in the bottle. French maritime pine bark extract is standardized to 65 to 75 percent procyanidins — oligomers of catechin and epicatechin from dimers up to chains of twelve or more — alongside phenolic acids and taxifolin.
  • Who it is forEndothelial and venous support; a reasonable adjunct alongside L-arginine or L-citrulline.
  • What to watchWell tolerated; GI upset, dizziness and headache.

How Pycnogenol works

French maritime pine bark procyanidins increase eNOS expression and protect nitric oxide from degradation, improving flow-mediated dilation. They also stabilize capillary walls by inhibiting the enzymes that degrade collagen and elastin in vessel basement membrane, which is why the same ingredient appears in venous insufficiency, retinopathy and skin trials.

Pycnogenol: serving, timing and spacing

Suggested serving
50–150 mg daily.
How often
Daily
When
With food, split

General referenceA general reference intake for education, not a prescription. The label on the product you buy is the final word.

Good to know

Antiplatelet activity — relevant before surgery and alongside anticoagulants. Expensive because it's patented; generic pine bark extracts are not the studied material.

Research on Pycnogenol5 evidence notes: clinical, correlative, theoretical

Each note sits under the kind of evidence it stands on. A thin or missing trial means nobody has run it yet, not that it doesn’t work. How the evidence tiers work

Human clinical evidence

  • Meta-analyses show improved endothelial function and modest blood pressure reduction.

  • Randomized trials support improvement in chronic venous insufficiency symptoms — leg swelling and heaviness.

  • Trials show reduced platelet aggregation and improved erectile function when combined with L-arginine.

Correlative data

  • Traditional use of pine bark by Indigenous North American peoples and, famously, the account of Jacques Cartier's crew recovering from scurvy on a bark and needle infusion in 1536. That was vitamin C rather than the proanthocyanidins, which is a useful reminder about attributing traditional outcomes to the wrong constituent.

Theoretical / extrapolated benefits

  • Procyanidins are proposed to increase nitric oxide availability, which fits the vascular findings coherently.

Sources read for this page

  • Weichmann F. Pycnogenol French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies. Front Nutr 2024 · PMID 38757130
  • Bayer J. Review of the pharmacokinetics of French maritime pine bark extract (Pycnogenol) in humans. Front Nutr 2024 · PMID 38757126
  • Mohammadi S. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complement Med Ther 2025 · PMID 39987124
  • Tian Y. Efficacy of L-arginine and Pycnogenol in the treatment of male erectile dysfunction: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2023 · PMID 37908749
  • Donovan EK. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster). Int J Environ Res Public Health 2021 · PMID 33802272

Pycnogenol, the deep readThe mechanism, cell to human, which form, how you would know

What Pycnogenol actually does

The extract is a polymer mixture, and the molecule that ends up doing the work is not in the bottle. French maritime pine bark extract is standardized to 65 to 75 percent procyanidins — oligomers of catechin and epicatechin from dimers up to chains of twelve or more — alongside phenolic acids and taxifolin. Oligomers above the dimer are too large to cross the intestinal epithelium intact.

Colonic bacteria depolymerize them into something absorbable, and that metabolite has a name. Gut microbiota convert procyanidins to delta-(3,4-dihydroxyphenyl)-gamma-valerolactone, labeled M1 in the pharmacokinetic literature, which appears in plasma hours after dosing and is measurable in urine Bayer 2024. M1 accumulates in macrophages and endothelial cells and is the strongest candidate for whatever systemic activity this extract has.

The proposed vascular mechanism is nitric oxide and enzyme inhibition rather than antioxidant scavenging. Constituents and metabolites stimulate endothelial nitric oxide synthase, inhibit angiotensin-converting enzyme in vitro, and inhibit matrix metalloproteinase-9 in cell systems. The venous-tone and edema claims rest on the last of those, through effects on capillary permeability.

There is a documented anti-inflammatory action at the transcription factor. Procyanidin metabolites inhibit nuclear factor kappa B activation and reduce interleukin-1 beta and cyclooxygenase-2 expression in stimulated cells, which is the mechanistic argument behind the osteoarthritis and inflammatory endpoints in the trial literature Weichmann 2024.

And there is a mechanism with no receptor at all, which is worth stating. Taxifolin and the free catechins are directly antioxidant in a cuvette. At the plasma concentrations achievable — nanomolar for parent compounds Bayer 2024 — that chemistry cannot be the mechanism, and any explanation of this extract that begins with free radical scavenging is describing a test tube.

Cell, rodent, human — and where it stops

This page has more randomized trials behind it than almost anything else in the catalog, and that is the problem rather than the recommendation.

The pharmacokinetics have now been characterized properly and they constrain everything. A review of the human pharmacokinetics establishes which constituents are measurable in plasma, over what time course, and that the microbial metabolite M1 rather than the administered procyanidins is what circulates Bayer 2024. Anybody reasoning from a procyanidin concentration in a dish is reasoning about an exposure that does not occur.

The trial literature is large, and its shape is the finding. A review of randomized, double-blind, placebo-controlled human clinical studies covers dozens of trials across venous insufficiency, osteoarthritis, asthma, cognitive function, skin, diabetes and endothelial function Weichmann 2024. Each is small, each uses a different marker, and independent replication of any single result is rare.

Where somebody pooled a defined endpoint the effect shrank. A systematic review and meta-analysis asking whether pine bark extract improves cardiometabolic risk factors found the answer more equivocal than the individual trials suggest Mohammadi 2025. That is the usual fate of a literature made of many small positive studies.

The obstacle to transfer is that most of the trial literature involves the manufacturer. The extract is a single proprietary product, most trials are conducted with company support, and independent replication is the exception. That does not make a result wrong; it means the usual correction for sponsorship applies, and it is why the independent trials matter more than their number suggests.

An independent trial is instructive here. A placebo-controlled crossover of botanical agents including French maritime pine bark in Gulf War Illness was run outside the manufacturer's program Donovan 2021, and the combination trial of L-arginine with this extract in erectile dysfunction Tian 2023 cannot attribute its effect to either component. Those two designs bracket the problem: independent trials are rare, and combination trials cannot answer the question.

Pycnogenol — which form, and does it matter

Pycnogenol is a trademark for one specific extract and the generic pine bark on a shelf is not it. The trial literature belongs to a standardized French maritime pine bark extract from Pinus pinaster with a defined procyanidin specification Weichmann 2024. Grape seed extract, generic pine bark from other species, and unstandardized bark powder are different procyanidin mixtures with different oligomer distributions.

The oligomer distribution is the specification that matters and no consumer label reports it. Effects depend on which chain lengths are present, because chain length decides both whether anything is absorbed intact and how efficiently gut bacteria depolymerize the rest Bayer 2024. Percent procyanidins constrains the total and says nothing about the distribution.

The exposure profile has two peaks and the second one is the interesting one. Catechin and taxifolin appear in plasma within roughly 30 minutes to 2 hours at nanomolar concentrations, with rapid glucuronidation and sulfation in the enterocyte and liver and renal clearance of the conjugates. The microbial metabolite M1 appears from about 6 hours and persists far longer, which is why chronic dosing produces a different exposure from a single dose and why the trials dose for weeks Bayer 2024.

That microbial step is the same lottery the urolithin page describes. Conversion capacity varies between people and falls after antibiotics, so two people on the same 100 mg capsule can have different systemic exposures for reasons neither of them can measure. No trial has stratified on it.

The dose range in the literature is wide and unexplained. Trials use anywhere from 40 mg to 360 mg a day, with 100 to 150 mg commonest, and no dose-ranging study establishes where the curve turns Weichmann 2024. A reader choosing a dose is choosing from a distribution of trial protocols rather than from a dose-response.

What would have to be true, and how you would know it was not

1. Predict a small change in an endothelial measure and predict it needs weeks. Predict a measurable improvement in flow-mediated dilation over 4 to 8 weeks at 100 to 150 mg a day in somebody with impaired baseline function, and much less in a healthy adult Weichmann 2024 Mohammadi 2025.

2. Predict the cardiometabolic markers move less than the individual trials suggest. Predict small or absent changes in lipid panel, HbA1c (hemoglobin A1c) and blood pressure at 12 weeks, because that is what pooling found Mohammadi 2025. Measure them and hold the product to the pooled estimate rather than to the best single trial.

3. The prediction that cuts against the product. Predict that an independent, adequately powered, non-manufacturer trial of a single indication returns a smaller effect than the sponsored literature Donovan 2021. A large independent replication confirming the effect sizes in the review would falsify this page's central caution and would be the most valuable study this extract could have.

4. Predict the microbial metabolite explains the non-responders. Predict that urinary M1 varies severalfold between people on the same dose, and that responders have higher M1 Bayer 2024. No trial has measured it alongside an outcome, which makes this a prediction rather than a finding.

5. Predict the combination trials cannot be split. Predict that a trial of this extract with L-arginine cannot attribute its effect Tian 2023, and that a factorial design would assign most of it to one arm. That design has not been run for any of the combinations this extract is sold in.

What nobody has tested yet

The independent replication is the missing study, and it is missing across every indication. Dozens of small trials with a single sponsor is a different evidence base from a handful of independent ones Weichmann 2024. One large independent trial in the best-supported indication would be worth more than another twenty small ones.

Nobody has stratified on the microbial converter. M1 is measurable Bayer 2024 and no trial has related it to response. That single addition to an existing protocol would explain most of the between-person variation and has not been made.

The dose-response has never been established. Trials span nearly an order of magnitude in daily dose with no systematic comparison Mohammadi 2025. Whether 40 mg does what 300 mg does is unknown, which is unusual for a product with this many trials.

And no outcome trial exists in any indication. Every endpoint in this literature is a marker, a symptom scale or a functional measure over weeks to months. Whether any of them translates into a clinical event has not been tested Weichmann 2024.

Pycnogenol — its own safety story, not its category's

Tolerability across the trial literature is good and the complaints are minor. Gastrointestinal upset, headache, dizziness and occasional nausea, generally mild and reduced by taking it with food Weichmann 2024. There is no established tolerable upper intake level.

The plausible interaction is antiplatelet and it is mechanistic. Procyanidins inhibit platelet aggregation in vitro and the extract has been studied for effects on platelet function, so adding it to aspirin, clopidogrel or an anticoagulant is an additive situation. Stopping two weeks before elective surgery costs nothing.

Immune stimulation is a documented mechanism and a specific caution. The extract has been reported to increase natural killer cell activity and to modulate cytokine production, which is a reason to raise it with a clinician in autoimmune disease and in anyone on an immunosuppressant after transplant.

The glucose effect is small and additive. Reductions in fasting glucose have been reported in diabetes trials Mohammadi 2025, which matters alongside insulin or a sulfonylurea rather than on its own.

Who this is not established for. Pregnancy and lactation, with no adequate data. Children, where trials exist in asthma and attention disorders but the safety base is thin. And anyone buying generic pine bark on the strength of this literature, which belongs to one standardized extract Weichmann 2024 Bayer 2024. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.

Pycnogenol safety basics3 points of its own

Its own safety story

  • Well tolerated; GI upset, dizziness and headache.
  • Mild antiplatelet activity and blood-glucose lowering — additive with anticoagulants and diabetes medication.
  • Immunostimulant activity, so caution with autoimmune disease and immunosuppressants. Not established as safe in pregnancy or breastfeeding — not because harm is documented, but because these are the two populations systematically excluded from the trials. Absence of data is not reassurance.

Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor. Pharmacists are underused and free.

Bloodwork to run4 tests in one order, code CAMERON

The effect itself has no blood test. That is a fact about the effect, and it changes how you should judge it.

  • What to watchStart with the label, because this is the rare botanical where the brand is the evidence: the trial base belongs to one patented, standardized pine bark extract, and a generic pine bark capsule is not the studied material. Then pick one endpoint and only one — leg heaviness and calf circumference at a marked point for the venous claim, or nothing at all for the endothelial claim, because flow-mediated dilation is an ultrasound in a vascular lab.
  • How long before it means anything8-12 weeks at 50-150 mg. Venous symptom trials in this class run on that scale, and the endothelial work is measuring something you cannot perceive at all, so there is no shorter honest window.
  • What will fool youThe erectile-function result people have heard about came from combining this with L-arginine rather than from the bark alone, so a single-ingredient bottle is not testing the study being quoted at you. It also has antiplatelet activity, which means easier bruising is a pharmacological signal rather than proof the vascular claim is landing — and a reason to stop well before any surgery.

The labs mapped to Pycnogenol

4 tests in one order
Marek Diagnostics · no doctor’s visit
Code CAMERON
Order these 4 tests

Code CAMERON applies automatically at checkout. Draw before you start, not after: a result with nothing to compare it to answers nothing.

The Real Cardiovascular Risk panel, explained

Pycnogenol FAQ5 common questions

What is Pycnogenol?
A standardized pine bark extract with an unusually large trial base for a botanical — largely because it's a single patented extract, so the studies are actually comparable.
What is the suggested dose of Pycnogenol?
50–150 mg daily. This is a general reference for education only. Statements have not been evaluated by the FDA and this is not medical advice.
Who is Pycnogenol for?
Endothelial and venous support; a reasonable adjunct alongside L-arginine or L-citrulline.
Which labs show whether Pycnogenol is doing anything?
ApoB (Apolipoprotein B), Lipoprotein(a) — Lp(a), hs-CRP (High-Sensitivity C-Reactive Protein), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides). Draw a baseline before you start, then recheck.
Where can I buy Pycnogenol?
Coach Cam sources Pycnogenol from vetted, top-rated brands on iHerb. Use the buy link on this page.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

The full stack plan is inside Skool

This page covers what Pycnogenol is, what the research says and how people take it. Skool puts it in order alongside everything else you run, peptides included.

Free on this page

What Pycnogenol is and how it works · The serving, its basis, and its safety lines · The research and the bloodwork that shows it

  • What Pycnogenol is and how it works
  • The serving, its basis, and its safety lines
  • The research and the bloodwork that shows it

Members get

  • Pycnogenol in your full stack: what it runs with, and what it cancels out
  • Its place in 2 Protocol Blueprints (Endurance, Libido & Sexual Function), week by week
  • The retest plan: ApoB (Apolipoprotein B) baseline, the recheck, what a change means
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational reference only. Not medical advice. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy on iHerbJoin Skool